An observational study in Steatotic Liver Disease, sponsored by Medical University of Vienna. Recruiting at 1 site in Austria. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Medical University of Vienna · Observational
Steatotic liver disease (SLD) is the most common chronic liver disease and is associated with an increased risk of liver-related complications, cardiovascular disease, and malignancies. However, comprehensive prospective data on the clinical characteristics, disease progression, and management of patients with SLD in Austria remain limited.
The SLD-AT study is a multicenter, prospective, observational registry with an associated biobank aiming to characterize patients with suspected or confirmed SLD in Austria. The registry will collect longitudinal clinical, laboratory, imaging, and treatment-related data to investigate disease progression, clinical outcomes, and the prognostic value of non-invasive tests and biomarkers.
The study aims to enroll approximately 20,000 participants over a planned duration of 15 years.
SLD-AT is a multicenter, prospective, observational registry designed to systematically investigate the epidemiology, clinical characteristics, risk factors, management, and long-term outcomes of patients with suspected or confirmed steatotic liver disease (SLD) in Austria.
Adult patients undergoing routine clinical evaluation at participating centers will be invited to participate. Clinical management will follow standard medical practice, without study-mandated therapeutic interventions.
Demographic, anthropometric, clinical, laboratory, and imaging data, including non-invasive assessments of liver fibrosis and steatosis, will be collected at baseline and during follow-up. Follow-up assessments will generally take place every 6-12 months, with longer intervals where clinically appropriate. Liver-related complications, cardiovascular events, malignancies, and mortality will be documented.
An associated biobank will collect and store biological samples, including blood and, where available, urine, stool, and residual liver tissue, for future biomarker research.
The registry aims to improve the understanding of the natural history of SLD, identify predictors of disease progression and clinical outcomes, and evaluate non-invasive diagnostic and prognostic tools in a real-world clinical setting. Approximately 20,000 patients are expected to be enrolled over a planned study duration of 15 years.
Medical University of Vienna is the lead sponsor of 1,109 studies on the registry; 184 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population comprises adult patients (18-100 years) with suspected or confirmed steatotic liver disease (SLD) undergoing routine clinical evaluation at participating healthcare centers in Austria. Patients will be recruited from outpatient clinics and inpatient settings. Eligible participants will be enrolled prospectively following written informed consent and followed longitudinally according to clinical needs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Number of participants developing compensated advanced chronic liver disease (cACLD), as assessed by liver stiffness measurement using vibration-controlled transient elastography (VCTE) >=10 kPa
The number and proportion of participants without cACLD at baseline who develop cACLD during longitudinal follow-up will be assessed using liver stiffness measurement (LSM, kPa) by vibration-controlled transient elastography (VCTE) with a cut-off \>=10 kPa. Disease progression will be characterized through repeated non-invasive assessments performed as part of routine clinical care. Analyses will primarily be descriptive and may include incidence rates and time-to-event analyses.
Time frame: 10 years
Plan to share: No — Individual patient data can be shared upon reasonable request and after fulfilling all data protection requirments from the EU.
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Dec 2040, 185 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Vienna →